Icon Plc (ICLR) Holdings Boosted by Nomura Holdings Inc.
Nomura Holdings Inc. grew its stake in shares of Icon Plc (NASDAQ:ICLR) by 12.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,549 shares of the medical research company’s stock after buying an additional 822 shares during the period. Nomura Holdings Inc.’s holdings in Icon Plc were worth $738,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently modified their holdings of the company. Shine Investment Advisory Services Inc. bought a new position in Icon Plc during the second quarter worth about $103,000. Acrospire Investment Management LLC boosted its holdings in Icon Plc by 20.1% during the second quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock worth $117,000 after buying an additional 200 shares during the last quarter. Parallel Advisors LLC boosted its holdings in Icon Plc by 20.7% during the second quarter. Parallel Advisors LLC now owns 1,265 shares of the medical research company’s stock worth $133,000 after buying an additional 217 shares during the last quarter. US Bancorp DE boosted its holdings in Icon Plc by 15.0% during the first quarter. US Bancorp DE now owns 1,929 shares of the medical research company’s stock worth $154,000 after buying an additional 251 shares during the last quarter. Finally, Huntington National Bank boosted its holdings in Icon Plc by 5.0% during the second quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock worth $159,000 after buying an additional 77 shares during the last quarter. Hedge funds and other institutional investors own 91.54% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was originally published by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/10/19/icon-plc-iclr-holdings-boosted-by-nomura-holdings-inc.html.
A number of brokerages have issued reports on ICLR. Zacks Investment Research cut Icon Plc from a “buy” rating to a “hold” rating in a report on Thursday, September 7th. Jefferies Group LLC reaffirmed a “buy” rating and set a $122.00 price target on shares of Icon Plc in a research report on Tuesday, September 12th. Robert W. Baird reaffirmed a “buy” rating and set a $123.00 price target on shares of Icon Plc in a research report on Thursday, October 12th. Bank of America Corporation assumed coverage on Icon Plc in a research report on Monday, September 11th. They set a “buy” rating and a $128.00 price target on the stock. Finally, ValuEngine raised Icon Plc from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. Icon Plc currently has an average rating of “Buy” and an average target price of $119.33.
Icon Plc (NASDAQ ICLR) opened at 114.49 on Thursday. Icon Plc has a 1-year low of $73.76 and a 1-year high of $117.53. The firm has a 50-day moving average price of $113.43 and a 200-day moving average price of $98.94. The company has a market capitalization of $6.19 billion, a P/E ratio of 23.22 and a beta of 0.59.
Icon Plc (NASDAQ:ICLR) last posted its quarterly earnings results on Thursday, July 27th. The medical research company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.01. The business had revenue of $431.00 million for the quarter, compared to the consensus estimate of $430.68 million. Icon Plc had a return on equity of 28.72% and a net margin of 15.97%. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.14 EPS. On average, analysts forecast that Icon Plc will post $5.32 EPS for the current fiscal year.
Icon Plc Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).
Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.